Inari Medical (NARI) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

NARI Stock Forecast

Inari Medical stock forecast is as follows: an average price target of $66.11 (represents a 30.76% upside from NARI’s last price of $50.56) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

NARI Price Target

The average price target for Inari Medical (NARI) is $66.11 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $86.00 to $50.00. This represents a potential 30.76% upside from NARI's last price of $50.56.

NARI Analyst Ratings

Buy

According to 11 Wall Street analysts, Inari Medical's rating consensus is 'Buy'. The analyst rating breakdown for NARI stock is 0 'Strong Buy' (0.00%), 6 'Buy' (54.55%), 4 'Hold' (36.36%), 0 'Sell' (0.00%), and 1 'Strong Sell' (9.09%).

Inari Medical Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 29, 2024	David Rescott	Robert W. Baird	$67.00	$49.27	35.99%	32.52%
Oct 29, 2024	Adam Maeder	Piper Sandler	$52.00	$42.56	22.18%	2.85%
Oct 29, 2024	William Plovanic	Canaccord Genuity	$74.00	$42.56	73.87%	46.36%
Oct 29, 2024	Richard Newitter	Truist Financial	$50.00	$42.56	17.48%	-1.11%
Oct 29, 2024	Marie Thibault	BTIG	$86.00	$42.56	102.07%	70.09%
Oct 15, 2024	David Rescott	Robert W. Baird	$66.00	$42.20	56.40%	30.54%
Sep 17, 2024	Mathew Blackman	Stifel Nicolaus	$50.00	$44.10	13.38%	-1.11%
Aug 09, 2024	Pito Chickering	Deutsche Bank	$68.00	$48.72	39.57%	34.49%
Jul 31, 2024	David Rescott	Robert W. Baird	$63.00	$52.11	20.90%	24.60%
Jul 31, 2024	Larry Biegelsen	Wells Fargo	$65.00	$52.11	24.74%	28.56%

Row per page

Go to

The latest Inari Medical stock forecast, released on Oct 29, 2024 by David Rescott from Robert W. Baird, set a price target of $67.00, which represents a 35.99% increase from the stock price at the time of the forecast ($49.27), and a 32.52% increase from NARI last price ($50.56).

Inari Medical Price Target by Period

	1M	3M	12M
# Anlaysts	5	7	12
Avg Price Target	$65.80	$63.57	$62.58
Last Closing Price	$50.56	$50.56	$50.56
Upside/Downside	30.14%	25.73%	23.77%

In the current month, the average price target of Inari Medical stock is $65.80, according to 5 Wall Street analysts offering twelve months forecast. The average price target represents a 30.14% increase as opposed to Inari Medical's last price of $50.56. This month's average price target is up 3.51% compared to last quarter, and up 5.15% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 29, 2024	Sandler O'Neill	Market Perform	Market Perform	Hold
Oct 29, 2024	Piper Sandler	Neutral	Neutral	Hold
Oct 29, 2024	Canaccord Genuity	Buy	Buy	Hold
Oct 29, 2024	BTIG	Buy	Buy	Hold
Oct 09, 2024	Wells Fargo	Market Perform	Market Perform	Hold
Oct 09, 2024	Truist Financial	Underperform	Underperform	Hold
Sep 17, 2024	Wells Fargo	Market Perform	Market Perform	Hold
Sep 17, 2024	Truist Financial	Underperform	Underperform	Hold
Aug 26, 2024	Wells Fargo	Buy	Buy	Hold
Aug 26, 2024	Truist Financial	Underperform	Underperform	Hold

Row per page

Go to

Inari Medical's last stock rating was published by Sandler O'Neill on Oct 29, 2024. The company gave NARI a "Market Perform" rating, the same as its previous rate.

Inari Medical Financial Forecast

Inari Medical Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$132.09M	$126.37M	$119.00M	$116.17M	$107.77M	$96.20M	$92.74M	$86.75M	$83.22M	$72.92M	$63.45M	$57.40M	$48.61M	$38.72M	$25.39M
Avg Forecast	$224.39M	$214.63M	$205.03M	$199.06M	$188.28M	$179.43M	$170.33M	$167.41M	$160.48M	$150.69M	$143.79M	$137.83M	$131.79M	$121.92M	$116.67M	$110.56M	$104.85M	$90.83M	$87.80M	$83.60M	$78.15M	$63.04M	$59.65M	$55.14M	$42.87M	$26.53M	$12.97M
High Forecast	$226.69M	$216.83M	$207.12M	$201.09M	$190.21M	$181.27M	$172.08M	$169.53M	$161.21M	$150.85M	$143.79M	$137.83M	$132.03M	$121.92M	$117.86M	$111.69M	$105.92M	$90.83M	$87.80M	$83.60M	$78.15M	$63.04M	$59.65M	$55.14M	$42.87M	$26.53M	$12.97M
Low Forecast	$222.40M	$212.73M	$203.21M	$197.29M	$186.61M	$177.84M	$168.82M	$165.77M	$159.82M	$150.52M	$143.79M	$137.83M	$131.53M	$121.92M	$115.63M	$109.58M	$103.92M	$90.83M	$87.80M	$83.60M	$78.15M	$63.04M	$59.65M	$55.14M	$42.87M	$26.53M	$12.97M
# Analysts	3	3	4	5	4	5	2	7	11	5	3	4	7	5	6	3	2	2	2	2	3	4	5	6	6	3	3
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.00%	1.04%	1.02%	1.05%	1.03%	1.06%	1.06%	1.04%	1.06%	1.16%	1.06%	1.04%	1.13%	1.46%	1.96%

Inari Medical's average Quarter revenue forecast for Mar 24 based on 4 analysts is $137.83M, with a low forecast of $137.83M, and a high forecast of $137.83M. NARI's average Quarter revenue forecast represents a 4.34% increase compared to the company's last Quarter revenue of $132.09M (Dec 23).

Inari Medical EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	3	3	4	5	4	5	2	7	11	5	3	4	7	5	6	3	2	2	2	2	3	4	5	6	6	3	3
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-10.78M	$2.11M	$5.21M	$1.82M	$-2.84M	$-7.50M	$-7.04M	$-1.39M	$3.42M	$-1.67M	$5.01M	$8.53M	$7.51M	$7.11M	$-3.04M
Avg Forecast	$6.61M	$6.32M	$6.04M	$5.86M	$5.55M	$5.29M	$5.02M	$4.93M	$4.73M	$4.44M	$4.24M	$-1.90M	$3.88M	$3.59M	$3.44M	$-1.73M	$5.01M	$2.93M	$2.83M	$-1.85M	$2.52M	$2.03M	$1.92M	$5.63M	$1.38M	$854.94K	$-3.38M
High Forecast	$6.68M	$6.39M	$6.10M	$5.92M	$5.60M	$5.34M	$5.07M	$4.99M	$4.75M	$4.44M	$4.24M	$-1.52M	$3.89M	$3.59M	$3.47M	$-1.39M	$6.02M	$2.93M	$2.83M	$-1.48M	$2.52M	$2.03M	$1.92M	$6.75M	$1.38M	$854.94K	$-2.70M
Low Forecast	$6.55M	$6.27M	$5.99M	$5.81M	$5.50M	$5.24M	$4.97M	$4.88M	$4.71M	$4.43M	$4.24M	$-2.29M	$3.87M	$3.59M	$3.41M	$-2.08M	$4.01M	$2.93M	$2.83M	$-2.22M	$2.52M	$2.03M	$1.92M	$4.50M	$1.38M	$854.94K	$-4.06M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-2.78%	0.59%	1.52%	-1.05%	-0.57%	-2.56%	-2.49%	0.75%	1.36%	-0.82%	2.61%	1.52%	5.44%	8.31%	0.90%

7 analysts predict NARI's average Quarter EBITDA for Dec 23 to be $3.88M, with a high of $3.89M and a low of $3.87M. This is 83.73% upper than Inari Medical's previous annual EBITDA (Sep 23) of $2.11M.

Inari Medical Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	3	3	4	5	4	5	2	7	11	5	3	4	7	5	6	3	2	2	2	2	3	4	5	6	6	3	3
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-4.67M	$3.16M	$2.08M	$-2.22M	$-5.80M	$-10.15M	$-10.19M	$-3.18M	$1.11M	$-2.80M	$4.07M	$7.47M	$6.99M	$6.50M	$-3.80M
Avg Forecast	$-10.66M	$-5.96M	$-4.61M	$-326.38K	$1.92M	$2.04M	$-170.20K	$-1.38M	$-1.27M	$-6.77M	$-11.27M	$-4.29M	$358.37K	$802.54K	$-7.33M	$-3.90M	$1.62M	$-14.41M	$-13.37M	$-4.17M	$2.18M	$-3.97M	$4.77M	$4.93M	$727.25K	$-2.21M	$-4.23M
High Forecast	$-10.54M	$-5.89M	$-4.55M	$-322.62K	$1.94M	$2.06M	$-168.23K	$1.04M	$1.27M	$-6.69M	$-11.14M	$-3.43M	$2.87M	$809.83K	$-7.24M	$-3.12M	$1.95M	$-14.41M	$-13.37M	$-3.34M	$2.18M	$-3.97M	$4.77M	$5.92M	$727.25K	$-2.21M	$-3.38M
Low Forecast	$-10.80M	$-6.04M	$-4.67M	$-330.73K	$1.89M	$2.01M	$-172.46K	$-5.53M	$-8.89M	$-6.86M	$-11.42M	$-5.15M	$-1.43M	$795.24K	$-7.42M	$-4.68M	$1.30M	$-14.41M	$-13.37M	$-5.01M	$2.18M	$-3.97M	$4.77M	$3.94M	$727.25K	$-2.21M	$-5.07M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-13.02%	3.94%	-0.28%	0.57%	-3.57%	0.70%	0.76%	0.76%	0.51%	0.71%	0.85%	1.52%	9.60%	-2.94%	0.90%

Inari Medical's average Quarter net income forecast for Dec 23 is $358.37K, with a range of $-1.43M to $2.87M. NARI's average Quarter net income forecast represents a -88.67% decrease compared to the company's last Quarter net income of $3.16M (Sep 23).

Inari Medical SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	3	3	4	5	4	5	2	7	11	5	3	4	7	5	6	3	2	2	2	2	3	4	5	6	6	3	3
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$101.49M	$88.28M	$85.59M	$85.70M	$80.12M	$75.83M	$73.16M	$63.73M	$54.47M	$56.10M	$42.90M	$36.90M	$31.39M	$23.08M	$18.88M
Avg Forecast	$159.43M	$152.49M	$145.67M	$141.43M	$133.77M	$127.49M	$121.02M	$118.95M	$114.02M	$107.06M	$102.16M	$87.40M	$93.63M	$86.63M	$82.89M	$79.45M	$79.88M	$63.94M	$61.81M	$58.85M	$55.01M	$44.37M	$41.99M	$24.35M	$30.17M	$18.68M	$9.13M
High Forecast	$161.06M	$154.05M	$147.16M	$142.88M	$135.14M	$128.79M	$122.26M	$120.45M	$114.54M	$107.18M	$102.16M	$104.88M	$93.80M	$86.63M	$83.74M	$95.34M	$95.86M	$63.94M	$61.81M	$58.85M	$55.01M	$44.37M	$41.99M	$29.22M	$30.17M	$18.68M	$9.13M
Low Forecast	$158.01M	$151.14M	$144.38M	$140.17M	$132.59M	$126.36M	$119.95M	$117.78M	$113.55M	$106.94M	$102.16M	$69.92M	$93.45M	$86.63M	$82.16M	$63.56M	$63.91M	$63.94M	$61.81M	$58.85M	$55.01M	$44.37M	$41.99M	$19.48M	$30.17M	$18.68M	$9.13M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.08%	1.02%	1.03%	1.08%	1.00%	1.19%	1.18%	1.08%	0.99%	1.26%	1.02%	1.52%	1.04%	1.24%	2.07%

Inari Medical's average Quarter SG&A projection for Mar 24 is $87.40M, based on 4 Wall Street analysts, with a range of $69.92M to $104.88M. The forecast indicates a -13.89% fall compared to NARI last annual SG&A of $101.49M (Dec 23).

Inari Medical EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	3	3	4	5	4	5	2	7	11	5	3	4	7	5	6	3	2	2	2	2	3	4	5	6	6	3	3
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.08	$0.06	$0.04	$-0.04	$-0.11	$-0.19	$-0.19	$-0.06	$0.02	$-0.06	$0.08	$0.15	$0.14	$0.13	$-0.16
Avg Forecast	$-0.18	$-0.10	$-0.08	$-0.01	$0.03	$0.03	$-0.00	$-0.02	$-0.02	$-0.12	$-0.19	$-0.16	$0.01	$0.01	$-0.13	$-0.23	$-0.17	$-0.25	$-0.23	$-0.08	$0.04	$-0.07	$0.08	$0.06	$0.01	$-0.04	$-0.17
High Forecast	$-0.18	$-0.10	$-0.08	$-0.01	$0.03	$0.04	$-0.00	$0.02	$0.02	$-0.11	$-0.19	$-0.16	$0.05	$0.01	$-0.12	$-0.22	$-0.17	$-0.25	$-0.23	$-0.08	$0.04	$-0.07	$0.08	$0.06	$0.01	$-0.04	$-0.17
Low Forecast	$-0.19	$-0.10	$-0.08	$-0.01	$0.03	$0.03	$-0.00	$-0.09	$-0.15	$-0.12	$-0.20	$-0.16	$-0.02	$0.01	$-0.13	$-0.23	$-0.17	$-0.25	$-0.23	$-0.08	$0.04	$-0.07	$0.08	$0.06	$0.01	$-0.04	$-0.17
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-13.39%	4.01%	-0.32%	0.18%	0.64%	0.77%	0.83%	0.80%	0.59%	0.88%	0.98%	2.65%	11.19%	-3.42%	0.91%

According to 7 Wall Street analysts, Inari Medical's projected average Quarter EPS for Dec 23 is $0.01, with a low estimate of $-0.02 and a high estimate of $0.05. This represents a -88.86% decrease compared to NARI previous annual EPS of $0.06 (Sep 23).

Inari Medical Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
OM	Outset Medical	$0.79	$11.00	1292.41%	Buy
LEGN	Legend Biotech	$38.19	$82.69	116.52%	Buy
PGNY	Progyny	$13.77	$25.29	83.66%	Hold
NARI	Inari Medical	$50.56	$66.11	30.76%	Buy
AXNX	Axonics	$70.98	$71.00	0.03%	Buy
SWAV	ShockWave Medical	$334.75	$258.17	-22.88%	Hold

NARI Forecast FAQ

Is Inari Medical a good buy?

Yes, according to 11 Wall Street analysts, Inari Medical (NARI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 54.55% of NARI's total ratings.

What is NARI's price target?

Inari Medical (NARI) average price target is $66.11 with a range of $50 to $86, implying a 30.76% from its last price of $50.56. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Inari Medical stock go up soon?

According to Wall Street analysts' prediction for NARI stock, the company can go up by 30.76% (from the last price of $50.56 to the average price target of $66.11), up by 70.09% based on the highest stock price target, and down by -1.11% based on the lowest stock price target.

Can Inari Medical stock reach $80?

NARI's highest twelve months analyst stock price target of $86 supports the claim that Inari Medical can reach $80 in the near future.

What is Inari Medical's current price target trend?

5 Wall Street analysts forecast a $65.8 price target for Inari Medical (NARI) this month, up 30.14% from its last price of $50.56. Compared to the last 3 and 12 months, the average price target increased by 25.73% and increased by 23.77%, respectively.

What are Inari Medical's analysts' financial forecasts?

Inari Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $705.46M (high $713.09M, low $699.05M), average EBITDA is $20.78M (high $21.01M, low $20.59M), average net income is $2.4M (high $4.88M, low $-1.799M), average SG&A $501.22M (high $506.64M, low $496.67M), and average EPS is $0.0411 (high $0.0835, low $-0.0308). NARI's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $843.1M (high $851.73M, low $835.63M), average EBITDA is $24.84M (high $25.09M, low $24.62M), average net income is $-21.551M (high $-21.303M, low $-21.838M), average SG&A $599.02M (high $605.15M, low $593.71M), and average EPS is $-0.369 (high $-0.365, low $-0.374).

Did the NARI's actual financial results beat the analysts' financial forecasts?

Based on Inari Medical's last annual report (Dec 2023), the company's revenue was $493.63M, beating the average analysts forecast of $480.94M by 2.64%. Apple's EBITDA was $-14.032M, missing the average prediction of $9.18M by -252.87%. The company's net income was $-1.636M, missing the average estimation of $-10.067M by -83.75%. Apple's SG&A was $361.06M, beating the average forecast of $342.61M by 5.39%. Lastly, the company's EPS was $-0.0288, missing the average prediction of $-0.332 by -91.32%. In terms of the last quarterly report (Dec 2023), Inari Medical's revenue was $132.09M, beating the average analysts' forecast of $131.79M by 0.23%. The company's EBITDA was $-10.782M, missing the average prediction of $3.88M by -377.73%. Inari Medical's net income was $-4.665M, missing the average estimation of $358.37K by -1401.73%. The company's SG&A was $101.49M, beating the average forecast of $93.63M by 8.39%. Lastly, the company's EPS was $-0.0822, missing the average prediction of $0.00614 by -1438.76%